IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blatt, A. N.
Right arrow Articles by Pepose, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blatt, A. N.
Right arrow Articles by Pepose, J. S.

Investigative Ophthalmology & Visual Science, Vol 34, 3459-3465, Copyright © 1993 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Prophylactic acyclovir effectively reduces herpes simplex virus type 1 reactivation after exposure of latently infected mice to ultraviolet B

AN Blatt, KA Laycock, RH Brady, P Traynor, DJ Krogstad and JS Pepose
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO 63110.

PURPOSE. To determine the potential efficacy and anatomic sites of action of prophylactic oral acyclovir using a murine model of ultraviolet-B-induced reactivation of herpes simplex 1 keratitis. METHODS. Latent infection with herpes simplex 1 (McKrae) was established in 80 National Institutes of Health inbred strain of mice. Forty of the mice were given acyclovir orally and the other 40 latently infected mice served as controls. Mice were exposed to 250 mJ/cm2 of ultraviolet-B radiation and killed on days 1, 2, 3, and 4 after ultraviolet-B radiation. Trigeminal ganglia and eyes from these mice were homogenized and incubated on Vero cell monolayers for recovery of reactivated virus. RESULTS. Based on the recovery of infectious virus after ultraviolet-B in treated versus control groups, acyclovir effectively reduced detectable viral reactivation at both the ocular level (P = 0.003) and the ganglionic level (P = 0.025). The numbers of viral culture-positive eye and trigeminal ganglia homogenates in the control group were 11 and 6 out of 40, respectively, compared to 1 and 0 out of 40 culture-positive eye and trigeminal ganglia homogenates in the acyclovir treated mice. Therapeutic serum levels of acyclovir were confirmed by high performance liquid chromatography. In the acyclovir- tested group, the single case of viral break-through at the ocular surface was not an acyclovir-resistant mutant. CONCLUSION. Prophylactic acyclovir effectively reduces the incidence of herpes simplex virus-1 reactivation after ultraviolet-B-induced reactivation in National Institutes of Health inbred strain of mice.


This article has been cited by other articles:


Home page
 J. Virol.Home page
E. Cantin, B. Tanamachi, and H. Openshaw
Role for Gamma Interferon in Control of Herpes Simplex Virus Type 1 Reactivation
J. Virol., April 1, 1999; 73(4): 3418 - 3423.
[Abstract] [Full Text]

Home page
 NEJMHome page
K. R. Wilhelmus, R. W. Beck, P. S. Moke, C. R. Dawson, B. A. Barron, D. B. Jones, H. E. Kaufman, N. Kurinij, R. D. Stulting, J. Sugar, et al.
Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease
N. Engl. J. Med., July 30, 1998; 339(5): 300 - 306.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the Association for Research in Vision and Ophthalmology